Eli Lilly has released Phase 3 trial results for orforglipron, its oral GLP-1 receptor agonist, showing weight loss results comparable to injectable semaglutide — a potential game-changer for obesity treatment accessibility.
Trial Highlights
The 1,800-participant ACHIEVE trial demonstrated that patients taking 36mg orforglipron daily lost an average of 14.7% of body weight over 52 weeks, compared to 2.3% in the placebo group.
- Once-daily pill form eliminates the need for weekly injections
- Manufacturing costs projected at 60% less than injectable GLP-1 drugs
- Gastrointestinal side effects were comparable to existing GLP-1 treatments
- Cardiovascular benefit signals observed but require dedicated outcome trial
Market Impact
Analysts project orforglipron could capture 30% of the GLP-1 market within two years of launch, potentially making weight loss medication accessible to millions who avoid injectable treatments. Eli Lilly plans to submit for FDA approval by Q3 2026.
